CHINA HEALTH GRP HD-10

F:VNL1 Germany Diagnostics & Research
Market Cap
$4.60 Million
€4.48 Million EUR
Market Cap Rank
#35372 Global
#4167 in Germany
Share Price
€0.00
Change (1 day)
-10.00%
52-Week Range
€0.00 - €0.03
All Time High
€0.07
About

China Health Group Inc., an investment holding company, researches and develops drugs, bio drugs, natural drugs, and synthetic drugs in the People's Republic of China. The company offers contracted pharmaceutical development and clinical research, and post market; and post launch market research, medical science, and medical market services. It also provides hospital management, clinical research… Read more

CHINA HEALTH GRP HD-10 (VNL1) - Net Assets

Latest net assets as of : €- EUR

Based on the latest financial reports, CHINA HEALTH GRP HD-10 (VNL1) has net assets worth €- EUR as of .

Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€-) and total liabilities (€-). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.

Key Net Assets Metrics

Metric Value
Current Net Assets €-
% of Total Assets 0%
Annual Growth Rate N/A
5-Year Change N/A
10-Year Change N/A
Growth Volatility N/A

CHINA HEALTH GRP HD-10 - Net Assets Trend (None–None)

This chart illustrates how CHINA HEALTH GRP HD-10's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.

Annual Net Assets for CHINA HEALTH GRP HD-10 (None–None)

The table below shows the annual net assets of CHINA HEALTH GRP HD-10 from None to None.

Year Net Assets Change
No yearly data available.

Equity Component Analysis

This analysis shows how different components contribute to CHINA HEALTH GRP HD-10's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

  • No equity composition insights available.

CHINA HEALTH GRP HD-10 Competitors by Market Cap

The table below lists competitors of CHINA HEALTH GRP HD-10 ranked by their market capitalization.

Equity Growth Attribution

This analysis shows how different factors contributed to changes in CHINA HEALTH GRP HD-10's equity between the two most recent reporting periods.

Insufficient data available to analyze equity growth attribution.

Book Value vs Market Value Analysis

This analysis compares CHINA HEALTH GRP HD-10's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Insufficient data available to analyze book value vs market value.

Capital Efficiency Dashboard

This dashboard shows how efficiently CHINA HEALTH GRP HD-10 utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Insufficient data available to analyze capital efficiency metrics.

Industry Comparison

This section compares CHINA HEALTH GRP HD-10's net assets metrics with peer companies in the Diagnostics & Research industry.

Industry Context

  • Industry: Diagnostics & Research
  • Average net assets among peers: $10,792,710,184
  • Average return on equity (ROE) among peers: -33.38%

Peer Company Comparison

Company Net Assets Return on Equity Debt-to-Equity Market Cap
CHINA HEALTH GRP HD-10 (VNL1) €- N/A N/A $1.33 Million
Spermosens AB (publ) (9R5) $23.64 Million -27.17% 0.09x $517.28K
BML Inc (BMZ) $81.13 Billion 8.19% 0.43x $462.01 Million
Genomic Vision Société Anonyme (G09) $3.07 Million -162.85% 1.21x $711.54K
ICON Public Limited Company (IJF) $1.85 Billion 17.96% 0.86x $6.43 Billion
Adicon Holdings Limited (K0U) $1.77 Billion 2.65% 1.64x $138.53 Million
WuXi XDC Cayman Inc. (L74) $1.48 Billion 10.52% 0.69x $2.11 Billion
NanoRepro AG (NN6) $57.61 Million 51.59% 0.37x $16.84 Million
PERRIGO (PGO) $24.67 Million -167.93% 0.99x $6.37K